Alemtuzumab for Immune-Related Myocarditis Due to PD-1 Therapy

Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis

Moslehi, J. J., Salem, J.-E., Sosman, J. A., Lebrun-Vignes, B., & Johnson, D. B. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30533-6 · Cited by 942

Immune Checkpoint Inhibitor-Associated Myocarditis

Ganatra, S., & Neilan, T. G. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0130 · Cited by 303

Cardiac troponin testing in idiopathic inflammatory myopathies and systemic sclerosis-spectrum disorders: biomarkers to distinguish between primary cardiac involvement and low-grade skeletal muscle disease activity

Hughes, M., Lilleker, J. B., Herrick, A. L., & Chinoy, H. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-206812 · Cited by 95

Alemtuzumab for Cytolytic Induction of Immunosuppression in Heart Transplant Recipients

Cahoon, W. D., Ensor, C. R., & Shullo, M. A. (2012) · Progress in Transplantation · doi:10.7182/pit2012241 · Cited by 15

Reflecting on the cardiac toxicity in non-small cell lung cancer in the era of immune checkpoint inhibitors therapy combined with thoracic radiotherapy

Luo, Y., Zeng, Z., Liu, Y., & Liu, A. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.189008 · Cited by 17

Unravelling the Acute, Chronic and Steroid-Refractory Management of High-Grade Neurological Immune-Related Adverse Events: A Call to Action

Malvaso, A., Giglio, P., Diamanti, L., Gastaldi, M., Vegezzi, E., Pace, A., Bini, P., & Marchioni, E. (2024) · Brain Sciences · doi:10.3390/brainsci14080764 · Cited by 17

Managing Select Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitors

Cheema, P. K., Iafolla, M. A. J., Abdel-Qadir, H. M., Bellini, A. B., Chatur, N., Chandok, N., Comondore, V. R., Cunningham, M. E., Halperin, I. J., Hu, A. C., et al. (2024) · Current Oncology · doi:10.3390/curroncol31100473 · Cited by 18

Pan-Cancer Analysis of Histone Methyltransferase KMT2D with Potential Implications for Prognosis and Immunotherapy in Human Cancer

Luo, G., Chen, G., Chen, P., & Zhou, J. (2022) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207325666220221092318 · Cited by 17

Cardiotoxicity induced by immune checkpoint inhibitor: The complete insight into mechanisms, monitoring, diagnosis, and treatment

Ganesh, S., Zhong, P., & Zhou, X. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.997660 · Cited by 16

State-of-the-Art Document on Optimal Contemporary Management of Cardiomyopathies

Seferovic, P. M., Polovina, M. M., Rosano, G. M. C., Bozkurt, B., Metra, M., Heymans, S. R. B., Müllens, W., Bauersachs, J. K., Sliwa, K. S., de Boer, R. A., et al. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.2979 · Cited by 16

Steroid-Refractory Myocarditis Induced by Immune Checkpoint Inhibitor Responded to Infliximab: Report of Two Cases and Literature Review

Tan, S., Chang, Q., Zeng, H., Wei, Q., Huang, Q. M., Pu, X., Li, W., Li, Y., & Tian, P. (2024) · Cardiovascular Toxicology · doi:10.1007/s12012-024-09918-6 · Cited by 16

Immune Checkpoint Inhibitor-Associated Myocarditis: Risk, Diagnosis, and Clinical Impact

Mauriello, A., Correra, A., Maratea, A. C., Cetoretta, V., Benfari, G., Ilardi, F., Cocchia, R., Lisi, M., Malagoli, A., Mandoli, G. E., et al. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15020814 · Cited by 15

Immune-Checkpoint Inhibitor-Related Myocarditis: Where We Are and Where We Will Go

Vergara, A., Felice, M. D., Cesaro, A., Gragnano, F., Pariggiano, I., Golia, E., Pasquale, A. D., Blasi, E., Fimiani, F., Monda, E., et al. (2023) · Angiology · doi:10.1177/00033197231201929 · Cited by 17

Case 30-2019: A 65-Year-Old Woman with Lung Cancer and Chest Pain

Guiney, T. E., Lopes, M. S., Kalra, M. K., Mooradian, M. J., Neilan, T. G., & Stone, J. R. (2019) · New England Journal of Medicine · doi:10.1056/nejmcpc1900423 · Cited by 15

Immune checkpoint inhibitor–associated myocarditis

Osinga, T. E., Oosting, S. F., van der Meer, P., de Boer, R. A., Kuenen, B. C., Rutgers, A., Bergmann, L., Munnink, T. H. O., Jalving, M., & van Kruchten, M. (2022) · Netherlands Heart Journal · doi:10.1007/s12471-021-01655-7 · Cited by 17

The Emerging Role of Tissue-Resident Memory CD8+ T Lymphocytes in Human Digestive Tract Cancers

Mei, X., Li, H., Zhou, X., Cheng, M., & Cui, K. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.819505 · Cited by 16

Navigating Cardiotoxicity in Immune Checkpoint Inhibitors: From Diagnosis to Long-Term Management

Nardin, S., Ruffilli, B., Costantini, P., Mollace, R., Taglialatela, I., Pagnesi, M., Chiarito, M., Soldato, D., Cao, D., Conte, B., et al. (2025) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd12070270 · Cited by 15

Overcoming the cardiac toxicities of cancer therapy immune checkpoint inhibitors

Irabor, O. C., Nelson, N. G., Shah, Y., Niazi, M. Z., Poiset, S., Storozynsky, E., Singla, D. K., Hooper, D. C., & Lu, B. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.940127 · Cited by 14

The Role of Single-Cell Profiling and Deep Immunophenotyping in Understanding Immune Therapy Cardiotoxicity

Huang, Y. V., Waliany, S., Lee, D., Galdos, F. X., Witteles, R. M., Neal, J. W., Fan, A. C., Maecker, H. T., Nguyen, P. K. P., Wu, S. M., et al. (2022) · JACC CardioOncology · doi:10.1016/j.jaccao.2022.08.012 · Cited by 15

Immune checkpoint inhibitor-induced inflammatory arthritis: identification and management

Williams, S. G., Mollaeian, A., Katz, J. D., & Gupta, S. (2020) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2020.1804362 · Cited by 14

Evolution of Immune Checkpoint Blockade–Induced Myocarditis Over 2 Years

Norwood, T. G., Lenneman, C. G., Westbrook, B. C., Litovsky, S. H., McKee, S. B., & Conry, R. M. (2020) · JACC Case Reports · doi:10.1016/j.jaccas.2019.11.076 · Cited by 14

How can we manage the cardiac toxicity of immune checkpoint inhibitors?

Poto, R., Marone, G., Pirozzi, F., Galdiero, M. R., Cuomo, A., Formisano, L., Bianco, R., Corte, C. M. D., Morgillo, F., Napolitano, S., et al. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1906860 · Cited by 14

Myasthenia gravis and myopathy after nivolumab treatment for non‐small cell lung carcinoma: A case report

Kim, J., Nam, T., Kim, J., Kho, B., Park, C., Oh, I., & Kim, Y. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.13177 · Cited by 13

Infectious Complications of Immune Checkpoint Inhibitors

Abers, M. S., & Lionakis, M. S. (2020) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2020.02.004 · Cited by 13

Pembrolizumab-induced Myasthenia Gravis: Literature Review of Ocular Manifestations and a Refractory Case

Dugena, O., Zheng, C., Taylor, J., & Wong, A. N. M. (2022) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000422 · Cited by 13

Prospective Clinical Trials to Advance the Study of Immune Checkpoint Inhibitor Toxicity

Cluxton, C. D., & Naidoo, J. (2023) · Current Oncology · doi:10.3390/curroncol30070502 · Cited by 13

Immune-related myocarditis in two patients receiving camrelizumab therapy and document analysis

Zhang, C., Qin, S., & Zuo, Z. (2021) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552211027339 · Cited by 13

Immune checkpoint inhibitor-related myocarditis: current understanding and potential diagnostic and therapeutic strategies

Turker, I., & Johnson, D. B. (2023) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2254218 · Cited by 12

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

Chen, Y. H., Kovács, T., Ferdinandy, P., & Varga, Z. V. (2024) · British Journal of Pharmacology · doi:10.1111/bph.16405 · Cited by 12

Therapeutic agents for steroid-refractory immune checkpoint inhibitor-related myocarditis: a narrative review

Wang, Y., Li, S., Shi, H., Guan, X., Wei, Q., & Chen, D. (2024) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt-24-114 · Cited by 12

Life-threatening immune checkpoint inhibitor-induced myocarditis and myasthenia gravis overlap syndrome treated with abatacept: a case report

Wakefield, C., Shultz, C. T., Patel, B. D., & Malla, M. (2021) · BMJ Case Reports · doi:10.1136/bcr-2021-244334 · Cited by 12

Immune Checkpoint Inhibitor-Associated Myocarditis: From Pathophysiology to Rechallenge of Therapy – a Narrative Review

Tedeschi, A., Camilli, M., Ammirati, E., Gentile, P., Palazzini, M., Conti, N., Verde, A., Masciocco, G., Foti, G., Giannattasio, C., et al. (2023) · Future Cardiology · doi:10.2217/fca-2022-0120 · Cited by 13

Endothelial cells adopt a pro-reparative immune responsive signature during cardiac injury

Long, H., Steimle, J. D., Canozo, F. J. G., Kim, J. H., Li, X., Morikawa, Y., Park, M., Turaga, D., Adachi, I., Wythe, J. D., et al. (2023) · Life Science Alliance · doi:10.26508/lsa.202201870 · Cited by 14

Molecular mechanisms and therapies of immune checkpoint inhibitor associated myocarditis: Update on recent developments

Li, J., Chen, L., Liu, X., Zhang, M., & Liu, X. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.09.006 · Cited by 11

Immune Mechanisms of Viral, Autoimmune, and Immune Checkpoint Inhibitor‐Associated Myocarditis

Jo, W., Sun, V., & Čiháková, D. (2026) · Immunological Reviews · doi:10.1111/imr.70111 · Cited by 12

Successful Treatment of Steroid-Refractory Checkpoint Inhibitor Myocarditis with Globulin Derived-Therapy: A Case Report and Literature Review

Barry, T., Gallen, R. A., Freeman, C. M., Agasthi, P., Pedrotty, D. M., Yang, M., Jokerst, C. E., Mookadam, F., Hardaway, B., Lemond, L. M., et al. (2021) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2021.04.018 · Cited by 12

Immune checkpoint inhibitor cardiotoxicity: Breaking barriers in the cardiovascular immune landscape

Zhu, H., Ivanovic, M., Nguyen, A., Nguyen, P. K. P., & Wu, S. M. (2021) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2021.07.006 · Cited by 11

Current landscape and tailored management of immune-related adverse events

Liu, W., Luo, Z., Liu, Y., & Sun, B. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1078338 · Cited by 10

Insight of immune checkpoint inhibitor related myocarditis

Pi, J.-K., Chen, X.-T., Zhang, Y., Chen, X.-M., Wang, Y.-C., Xu, J., Zhou, J.-H., Yu, S.-S., & Wu, S. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113559 · Cited by 11

Therapeutic plasma exchange in the management of immune checkpoint inhibitor‐associated immune‐related adverse effects: A review

Onwuemene, O. A., Nnoruka, C. I., Patriquin, C. J., & Connelly‐Smith, L. S. (2022) · Transfusion · doi:10.1111/trf.17114 · Cited by 10

Pacemakers and methylprednisolone pulse therapy in immune-related myocarditis concomitant with complete heart block

Hu, C., Zhao, L., Zhou, C., Wang, H., Jiang, S., Li, Y., Peng, Y., Deng, C., Ma, F., Pan, Y., et al. (2022) · Open Medicine · doi:10.1515/med-2022-0611 · Cited by 10

Research Progress on Flavonoids in Traditional Chinese Medicine to Counteract Cardiotoxicity Associated with Anti-Tumor Drugs

Shi, H., Duan, L., Tong, L., Pu, P., Wei, L., Wang, L., Hu, D., & Tang, H. Y. (2024) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2503074 · Cited by 9

Acute heart failure: mechanisms and pre-clinical models—a Scientific Statement of the ESC Working Group on Myocardial Function

Ciccarelli, M., Falcão‐Pires, I., Bauersachs, J. K., Bertrand, L., Beauloye, C., Dawson, D. K., Hamdani, N., Hilfiker‐Kleiner, D., Laake, L. W. V., Lezoualc’h, F., et al. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvad088 · Cited by 9

Advanced materials for management of immune-related adverse events induced by immune checkpoint inhibitors

Zheng, L., Yang, X., Wei, Y., You, J., Li, H., Liao, J., & Cheng, Y. (2022) · Materials & Design · doi:10.1016/j.matdes.2022.110738 · Cited by 9

Mogamulizumab-Associated Acute Myocarditis in a Patient With T-Cell Lymphoma

Kwan, J. M., Odanovic, N. R., Arbune, A., Higgins, A. Y., Henry, M. L., Greif, D. M., Foss, F. M., & Baldassarre, L. A. (2021) · JACC Case Reports · doi:10.1016/j.jaccas.2021.04.001 · Cited by 9

Immunomodulating and Immunosuppressive Therapy for Virus-Negative Immune-Mediated Myocarditis

Frustaci, A., Letizia, C., Alfarano, M., Marchionni, G., Verardo, R., & Chimenti, C. (2024) · Biomedicines · doi:10.3390/biomedicines12071565 · Cited by 8

Ультразвукова характеристика функціональних змін міокарда при застосуванні кондиційованого середовища мезенхімальних стовбурових клітин на моделі автоімунного міокардиту

Hladkykh, F. V., Liadova, T. I., Komorovsky, R., & Chyzh, M. (2024) · Ukrainian Journal of Cardiology · doi:10.31928/2664-4479-2024.6.3546 · Cited by 9

T cells in acute and chronic myocarditis: from diagnosis to treatment

Song, E. J., Joachimbauer, A., Tasca, S., Baylis, R. A., Schmidt, D., Ludewig, B., & Moslehi, J. J. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehaf1080 · Cited by 8

Evaluating the effect of PD-1 inhibitors on left ventricular function in lung cancer with noninvasive myocardial work

Li, X., Wang, C., Kang, R., Zhao, Y., Chen, L., Liu, F., Wang, X., Peng, Y., & Zhang, C. (2023) · Quantitative Imaging in Medicine and Surgery · doi:10.21037/qims-22-817 · Cited by 8

PD-1 inhibitors-associated myocarditis in non-small cell lung cancer patients

He, Y., Chen, W., Cai, J., Luo, C., Zhou, C., & Li, X. (2023) · Journal of Thoracic Disease · doi:10.21037/jtd-23-596 · Cited by 8

Immune Checkpoint Inhibitors and Their Cardiovascular Adverse Effects

Paluri, R. K., Pulipati, Y., & Regalla, D. K. R. (2023) · Oncology Reviews · doi:10.3389/or.2023.11456 · Cited by 8

Cardiovascular Health Considerations for Primary Care Physicians Treating Breast Cancer Survivors

Kidane, R. D., Ruddy, K. J., Lin, G. R., & Sandhu, N. P. (2024) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2024.08.014 · Cited by 8

Immune Checkpoint Inhibitor Associated Rheumatic Adverse Events: a Review of Their Presentations and Treatments

Ye, C., Jamal, S., Hudson, M., Fifi-Mah, A. V., & Roberts, J. (2019) · Current Treatment Options in Rheumatology · doi:10.1007/s40674-019-00131-z · Cited by 9

Immune checkpoint inhibitor-associated myocarditis: a review of current state of knowledge

Ostos-Mendoza, K. C., Saraiba-Rabanales, V., Gutierrez‐Gallegos, P., Wang, E., Koutroumpakis, E., Kumar, S., Khalaf, S. Z., Ali, H.-J., Deswal, A. M., & Palaskas, N. L. (2025) · The Journal of Cardiovascular Aging · doi:10.20517/jca.2024.13 · Cited by 7

How should immune checkpoint inhibitor myocarditis be treated?

Badaan, S., Abbass, A., Tov, S., Bar‐Sela, G., & Bisharat, N. (2025) · Cardio-Oncology · doi:10.1186/s40959-025-00404-8 · Cited by 6

Therapeutic management of inflammatory heart diseases

Bonaventura, A., Buono, M. G. D., Golino, M., Potere, N., Vecchié, A., Malandrino, D., Tassell, B. W. V., Youngstein, T., Weber, B. N., & Abbate, A. (2026) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2026.108996 · Cited by 6

Immune checkpoint inhibition of metastatic melanoma: achieving high efficacy in the face of high toxicity

Justice, J. B., Kankaria, R. A., & Johnson, D. B. (2024) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2024.2431513 · Cited by 7

Toxicity Associated with Immune Checkpoint Inhibitors: Analysis of Immune-Related Adverse Events with a Pembrolizumab Biosimilar (Pembroria)

Fedyanin, M. Y., Владимирович, С. А., Breder, V. V., Linkova, Y. N., Zinkina-Orikhan, A. V., Setkina, S. B., Фогт, С. Н., Chistyakov, V., & Kravtsova, N. A. (2023) · Safety and Risk of Pharmacotherapy · doi:10.30895/2312-7821-2023-11-2-360 · Cited by 6

Neurologic manifestations of autoimmunity with immune checkpoint inhibitors

McCombe, J. A., Sechi, E., & Ζεκερίδου, Α. (2024) · Handbook of clinical neurology · doi:10.1016/b978-0-12-823912-4.00024-4 · Cited by 6

Testing Immune-Related Adverse Events in Cancer Immunotherapy

Farmer, J. R. (2019) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2019.07.012 · Cited by 6

Immune Checkpoint Inhibitor (ICI)-Related Cardiotoxicity

Zarifa, A., Lopez‐Mattei, J., Palaskas, N. L., Iliescu, C., Durand, J., & Kim, P. Y. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-79308-1_15 · Cited by 6

Metabolic consequences of immune checkpoint inhibitors: A new challenge in clinical practice

Parthymos, I., Liamis, G. L., Dounousi, E. C., Pentheroudakis, G. E., Mauri, D., Zarkavelis, G., & Florentin, M. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102979 · Cited by 6

Overall Survival in Heart Disease–Related Death in Non-Small Cell Lung Cancer Patients: Nonimmunotherapy Versus Immunotherapy Era: Population-Based Study

Safi, M., Kanesvaran, R., Alradhi, M., Al-Danakh, A., Ping, F., Al-Sabai, N., Shan, X., & Liu, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.572380 · Cited by 6

Immune checkpoint inhibitor-induced myocarditis: focus on the downstream pathogenic components and potential therapeutics

Chen, Y., Wang, X., Shen, Y., Zhang, H., Yu, C., Cheng, L., & Ge, J. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.12.004 · Cited by 5

Treatment of Myositis Associated With Immune Checkpoint Inhibitors

Matas-García, A., Martínez‐Hernández, E., & Milisenda, J. C. (2023) · Current Treatment Options in Rheumatology · doi:10.1007/s40674-023-00212-0 · Cited by 5

The Good (Tumor Killing) and the Bad (Cardiovascular Complications) of Immunologic Checkpoint Inhibitors

Gamero, M. T., Patel, A., & Storozynsky, E. (2024) · Current Cardiology Reports · doi:10.1007/s11886-024-02147-x · Cited by 5

Steroid-Refractory Immune Checkpoint Inhibitor–Induced Myocarditis Responsive to Mycophenolate and Antithymocyte Globulin

Wilson, M. J., Dabdoub, J., Gottbrecht, M. F., Salazar, R., & Shih, J. A. (2025) · JACC Case Reports · doi:10.1016/j.jaccas.2025.105139 · Cited by 5

Immune checkpoint inhibitor‐related myocarditis in thymic epithelial tumors: Recent progress and perspectives

Yin, J., Yao, Z., Pan, J., Gan, L., & Xue, J. (2023) · MedComm – Oncology · doi:10.1002/mog2.31 · Cited by 4

An autopsy case of lung adenocarcinoma with immune checkpoint inhibitor-induced pneumonia and fulminant myocarditis following pembrolizumab administration: a case report

Hashimoto, T., Takahashi, K., Ito, K. R., Iwade, K., Torii, A., Sugihara, M., Kondo, H., & Hara, T. (2024) · International Cancer Conference Journal · doi:10.1007/s13691-024-00665-7 · Cited by 5

What the Cardiologist Needs to Know About Cancer Immunotherapies and Complications

Frayberg, M., Yung, A., Zubiri, L., Zlotoff, D. A., & Reynolds, K. L. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00844-1 · Cited by 5

New insights gained from cellular landscape changes in myocarditis and inflammatory cardiomyopathy

Wang, W., Jia, H., Hua, X., & Song, J. (2024) · Heart Failure Reviews · doi:10.1007/s10741-024-10406-w · Cited by 4

Cardioselectivity of cryobiotechnological agents in the treatment of cardiovascular diseases

Hladkykh, F. V., Liadova, T. I., Chyzh, M., Komorovsky, R., Matvieienko, M. S., & Babayeva, H. H. (2025) · doi:10.46879/2025.4 · Cited by 4

Blood Sample Processing and Banking for Functional and Molecular Analyses

Thébault, P., Cailhier, J., & Lapointe, R. (2023) · Methods in molecular biology · doi:10.1007/978-1-0716-2914-7_3 · Cited by 4

Alemtuzumab and Fatal Myocarditis

Scolding, N. J., Ali, H., Sheppard, M. N., & Simon, A. R. (2020) · Neurology Clinical Practice · doi:10.1212/cpj.0000000000000772 · Cited by 4

Reply to ‘Personalized treatment of immune-related adverse events — balance is required’

Esfahani, K., & Calabrese, L. H. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0401-3 · Cited by 4

Cardiotoxicity Related to Immune Checkpoint Inhibitors: A Real-World Retrospective Analysis

She, J., Liu, H., Wu, H., Tuerhongjiang, G., Zheng, T., & Bai, L. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.838488 · Cited by 3

The role of immune checkpoint inhibitors in the development and treatment of infectious processes

Mustafina, D. A., Bagautdinova, A. N., Zinatullina, M. M., Gorbunov, N., Zainetdinova, E. T., Bukharmetova, D. I., Leonov, D. Y., Pirmagomedova, A. G., Chernyshova, A. E., Markhanos, M. P., et al. (2024) · Journal of clinical practice · doi:10.17816/clinpract627504 · Cited by 3

Vaccinations in Children and Adolescents Treated With Immune-Modifying Biologics: Update and Current Developments

Martire, B., Ottaviano, G., Sangerardi, M., Sgrulletti, M., Chini, L., Dellepiane, R. M., Montin, D., Rizzo, C., Pignata, C., Marseglia, G. L., et al. (2022) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2022.01.007 · Cited by 3

Ganoderma atrum polysaccharide interferes with TLR4 against PD-1 inhibitors-induced carditis via NF-κB-NLRP3 pathway driven by IRF1/VEGFA/14–3-3γ axis in Lewis lung carcinoma mice

Wang, J., Mu, X.-Y., Wang, W., Li, Y., Gui, Y.-Q., Peng, X., Chen, X., & Li, W. (2025) · Journal of Functional Foods · doi:10.1016/j.jff.2025.106732 · Cited by 2

Refractory ventricular arrhythmia in a patient with suspected immune checkpoint inhibitor-related myocarditis: a case report

Jin, X., & Zheng, R. (2025) · European Heart Journal - Case Reports · doi:10.1093/ehjcr/ytaf540 · Cited by 2

Pathological mechanisms and treatment strategies for immune checkpoint inhibitor-associated myocarditis: insights from single-cell sequencing

Zhao, Y., Lu, Y., Fu, T., Zhang, J., & Tang, J. (2026) · Basic Research in Cardiology · doi:10.1007/s00395-025-01156-3 · Cited by 2

Myocardial involvement in inflammatory myopathies: from subclinical disease to life-threatening myocarditis

Gil‐Vila, A., Araguás, E. T., Edo-Fernandez, C., Pinal‐Fernandez, I., Uribarri, A., Cuéllar, H., & Selva-O’Callaghan, A. (2026) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2026.2625281 · Cited by 2

The immunopathogenesis of rheumatic immune adverse events from checkpoint inhibitors: prospects for targeted therapy

Calabrese, L. H., & Calabrese, C. M. (2020) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000684 · Cited by 2

Recommendations and exploration of diagnosis and treatment of critical and refractory immune checkpoint inhibitor‐associated adverse events

Song, P., Wang, H., Si, X., Guo, X., Li, Y., Zhou, J., Duan, L., Zhang, L., & Wang, M. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13553 · Cited by 2

Cardioprotection of High-Risk Individuals

Upshaw, J. N., Mohanty, S., & Rastogi, A. (2022) · Heart Failure Clinics · doi:10.1016/j.hfc.2022.02.001 · Cited by 2

Immune Checkpoint Inhibitors - New Insights and Recent Progress

Raza, A. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.100958 · Cited by 2

Cardiovascular Toxicity Associated With Immune Checkpoint Inhibitor Therapy: A Comprehensive Review

Chitsazan, M., Amin, A., Ladel, L., Baig, A., & Chitsazan, M. (2023) · Critical Pathways in Cardiology A Journal of Evidence-Based Medicine · doi:10.1097/hpc.0000000000000327 · Cited by 2

Smoldering Myocarditis Unmasked by Pembrolizumab-Induced Myositis

Mark, J. D., Tapia-Orihuela, R. K. A., Llanos, A., CHARNICK, B., Stone, J. R., Muniz, J., & Collado, E. (2025) · JACC Case Reports · doi:10.1016/j.jaccas.2025.105069 · Cited by 1

A case series and literature review of immune checkpoint inhibitors-associated myocarditis (ICIM) in non-small cell lung cancer

Sun, Y., Liu, Y., Wang, Y., Dai, X., Lin, S., Bi, J., Zhang, J., Song, Y., Jiang, J., & Chen, S. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1615085 · Cited by 1

Case Report: Successful treatment of steroid-refractory immune checkpoint inhibitor associated myocarditis with tofacitinib

Kong, D., Zhang, F. C., Liu, Y., Zhu, X., Yuan, T., Liu, A., Zhou, L., Chen, W., & Yao, Q. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1778284 · Cited by 1

Key immune checkpoint inhibitor-associated toxicities: from molecular mechanisms to clinical management

Lu, T., Song, X., Zhang, T., & Ge, W. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1810121 · Cited by 1

Refining the treatment of immune checkpoint inhibitor–associated myocarditis: Challenges, innovations and rechallenge considerations

Mincu, R. I., Zimmer, L., Vlachopoulou, D., Haj‐Yehia, E., Hoffmann, J., Michel, L., Livingstone, E., Schadendorf, D., Tasdogan, A., Totzeck, M., et al. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70536 · Cited by 1

Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor-associated myocarditis (2026 edition)

Yan, W., Qingqing, C., Yuan, L., Jiahui, C., Hao, L., Jinyi, L., Zhiming, W., Yinman, W., Zhifeng, Y., Shilong, Z., et al. (2026) · Clinical Cancer Bulletin · doi:10.1007/s44272-026-00065-3 · Cited by 1

Fulminant Myocarditis Complicated with Immune Checkpoint Inhibitor in Patients with Thymoma: Report of Three Cases

Huang, D., Song, F., Zhang, W., Ma, H., Lin, X., Qin, T., & Wang, S. (2023) · International Journal of Cardiovascular Practice · doi:10.5812/intjcardiovascpract-130990 · Cited by 1

Mechanistic Insights into Drug-Induced Guillain–Barré Syndrome: A Large-Cohort Analysis of the FAERS Database

Gui, J., Li, X., Chu, H., Zhang, J., Dong, M., Zhang, F., Li, R., Luo, H., Gao, K., & Jiang, Y. (2025) · Pharmaceuticals · doi:10.3390/ph18040498 · Cited by 1

[Diagnosis and Treatment Recommendation and Exploration for Critical and Refractory Adverse Effects Related to Immunocheckpoint Inhibitors].

Wang, H., Song, P., Si, X., Guo, X., Li, Y., Zhou, J., Duan, L., Zhang, L., Wang, M., & Zhang, L. (2019) · PubMed Central · doi:10.3779/j.issn.1009-3419.2019.10.01 · Cited by 1

Cardiotoxicity from Immune Checkpoint Inhibitors: Myocarditis

Onderko, L. L., Bennett, E., & Francis, S. A. (2022) · Journal of Maine Medical Center · doi:10.46804/2641-2225.1104 · Cited by 1

Cardiotoxicité des inhibiteurs de points de contrôle immunitaire utilisés dans le traitement des cancers

Arangalage, D., Pavon, A. G., Hugelshofer, S., Desgraz, B., Τζίμας, Γ., Delyon, J., Müller, O., Obéid, M., Ribi, C., Michielin, O. A., et al. (2020) · JMIG · doi:10.53738/revmed.2020.16.696.1165 · Cited by 1

Rare forms of inflammatory myopathies – part I, generalized forms

Galluzzo, C., Chiapparoli, I., Corrado, A., Cantatore, F. P., Salvarani, C., & Pipitone, N. (2022) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2023.2154656 · Cited by 1

Research Progress on Cardiotoxicity Associated with Immune Checkpoint Inhibitors

赵, 紫. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.13102348 · Cited by 1

Neue onkologische Therapien und ihre kardiovaskulären Risiken

Totzeck, M., & Rassaf, T. (2020) · Herz · doi:10.1007/s00059-020-04902-6

Immune Associated Myocarditis: A Report of 2 Cases and Literature Review

冯, 志. (2020) · Asian Case Reports in Emergency Medicine · doi:10.12677/acrem.2020.83005

Management of Rheumatic Immune-Related Adverse Events (irAEs): General Principles

Meara, A. S., & Calabrese, L. H. (2021) · Springer eBooks · doi:10.1007/978-3-030-56824-5_14

Cardiovascular Oncologic Emergencies

Nafee, T., Debs, D., Planek, M. I. C., Zimmerman, A., Charlton, T., Dimza, M., Murphy, A. C., Dobbin, S. J. H., Lang, N. N., Tyebally, S. M., et al. (2021) · Springer eBooks · doi:10.1007/978-3-030-67123-5_21

Tocilizumab for Fulminant Programmed Death 1 Inhibitor–Associated Myocarditis

Wang, H., Tian, R., Gao, P., Wang, Q., & Zhang, L. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.09.080 · Cited by 25

Avelumab-Induced Myocarditis: A Case of Steroid-Refractory Immune Checkpoint Inhibitor Cardiotoxicity

Nirthanakumaran, D., Chiswell, K., Moussad, A., Gurney, H., & Brown, M. R. (2026) · Heart Lung and Circulation · doi:10.1016/j.hlc.2026.07.381

Case Analysis of Immune-Related Myocarditis Induced by PD-1 Inhibitors

史, 婉. (2022) · Advances in Clinical Medicine · doi:10.12677/acm.2022.123280

Plasma exchange plus glucocorticoids in the treatment of immune checkpoint inhibitor‐induced myocarditis: A case series and review

Ke, G., Chen, P., Luo, J., Huang, J., Shang, Y., Huang, Y., Fu, N., Peng, H., Li, Y., Wang, B., et al. (2023) · Clinical Cardiology · doi:10.1002/clc.24149 · Cited by 10

Use of Infliximab in the Treatment of Immune Checkpoint Inhibitors-Related Myocarditis: A Systematic Review of Case Reports

PHING, K. C., Gnanasan, S., & Tangiisuran, B. (2024) · Malaysian Journal of Pharmaceutical Sciences · doi:10.21315/mjps2024.22.1.7